Talphera (NASDAQ:TLPH – Get Free Report) is expected to announce its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect Talphera to post earnings of ($0.06) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.
Talphera (NASDAQ:TLPH – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). On average, analysts expect Talphera to post ($0.23) EPS for the current fiscal year and ($0.27) EPS for the next fiscal year.
Talphera Stock Performance
Shares of NASDAQ TLPH opened at $1.05 on Wednesday. The firm’s fifty day moving average is $1.14 and its two-hundred day moving average is $1.01. Talphera has a 52-week low of $0.69 and a 52-week high of $1.57. The company has a market cap of $54.40 million, a P/E ratio of -3.85 and a beta of 0.77.
Analyst Ratings Changes
Several research firms have issued reports on TLPH. Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a research report on Thursday, October 15th. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Talphera in a research report on Thursday, August 13th. Finally, Wall Street Zen upgraded Talphera to a “hold” rating in a research note on Saturday, August 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Talphera has a consensus rating of “Hold” and a consensus price target of $3.00.
Check Out Our Latest Stock Report on Talphera
About Talphera
Talphera, formerly known as AcelRx Pharmaceuticals, is a specialty pharmaceutical company focused on developing and commercializing therapies for acute pain. The company’s lead product is DSUVIA, a sublingual tablet containing sufentanil, an opioid analgesic designed to provide rapid relief for adults experiencing acute pain severe enough to require an opioid.
DSUVIA is intended for use in medically supervised settings, including hospitals, surgical centers and other certified health-care environments.
Featured Stories
- Five stocks we like better than Talphera
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
